-
Je něco špatně v tomto záznamu ?
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
P. Kawalec, T. Tesar, L. Vostalova, P. Draganic, M. Manova, A. Savova, G. Petrova, Z. Rugaja, A. Männik, C. Sowada, E. Stawowczyk, A. Harsanyi, A. Inotai, A. Turcu-Stiolica, J. Gulbinovič, A. Pilc,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
29326583
DOI
10.3389/fphar.2017.00892
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Objectives: The aim of this study was to review reimbursement environment as well as pricing and reimbursement requirements for drugs in selected Central and Eastern Europe (CEE) countries.Methods:A questionnaire-based survey was performed in the period from November 2016 to March 2017 among experts involved in reimbursement matters from CEE countries: Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania. A review of requirements for reimbursement and implications of Health Technology Assessment (HTA) was performed to compare the issues in above-mentioned countries. For each specified country, data for reimbursement costs, total pharmaceutical budget, and total public health care budget in the years 2014 and 2015 were also collected. Questionnaires were distributed via emails and feedback data were obtained in the same way. Additional questions, if any, were also submitted to respondents by email. Pricing and reimbursement data were valid for March 2017.Results:The survey revealed that the relation of drug reimbursement costs to total public healthcare spending ranged from 0.12 to 0.21 in the year 2014 and 2015 (median value). It also revealed that pricing criteria for drugs, employed in the CEE countries, were quite similar. External reference pricing as well as internal reference pricing were common in mentioned countries. Positive reimbursement lists were valid in all countries of the CEE region, negative ones were rarely used; reimbursement decisions were regularly revised and updated in the majority of countries. Copayment was common and available levels of reimbursement differed within and between the countries and ranged from 20 to 100%. Risk-sharing schemes were often in use, especially in the case of innovative, expensive drugs. Generic substitution was also possible in all analyzed CEE countries, while some made it mandatory. HTA was carried out in almost all of the considered CEE countries and HTA dossier was obligatory for submitting a pricing and reimbursement application.Conclusions:Pricing and reimbursement requirements are quite similar in the CEE region although some differences were identified. HTA evaluations are commonly used in considered countries.
Croatian Agency for Medicinal Products and Medical Devices Zagreb Croatia
Faculty of Pharmacy Medical University of Sofia Sofia Bulgaria
Faculty of Pharmacy University of Medicine and Pharmacy of Craiova Craiova Romania
Institute of Family Medicine and Public Health University of Tartu Tartu Estonia
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010090
- 003
- CZ-PrNML
- 005
- 20180404145428.0
- 007
- ta
- 008
- 180404s2017 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2017.00892 $2 doi
- 035 __
- $a (PubMed)29326583
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kawalec, Paweł $u Health Sciences Faculty, Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland.
- 245 10
- $a Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review / $c P. Kawalec, T. Tesar, L. Vostalova, P. Draganic, M. Manova, A. Savova, G. Petrova, Z. Rugaja, A. Männik, C. Sowada, E. Stawowczyk, A. Harsanyi, A. Inotai, A. Turcu-Stiolica, J. Gulbinovič, A. Pilc,
- 520 9_
- $a Objectives: The aim of this study was to review reimbursement environment as well as pricing and reimbursement requirements for drugs in selected Central and Eastern Europe (CEE) countries.Methods:A questionnaire-based survey was performed in the period from November 2016 to March 2017 among experts involved in reimbursement matters from CEE countries: Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Romania. A review of requirements for reimbursement and implications of Health Technology Assessment (HTA) was performed to compare the issues in above-mentioned countries. For each specified country, data for reimbursement costs, total pharmaceutical budget, and total public health care budget in the years 2014 and 2015 were also collected. Questionnaires were distributed via emails and feedback data were obtained in the same way. Additional questions, if any, were also submitted to respondents by email. Pricing and reimbursement data were valid for March 2017.Results:The survey revealed that the relation of drug reimbursement costs to total public healthcare spending ranged from 0.12 to 0.21 in the year 2014 and 2015 (median value). It also revealed that pricing criteria for drugs, employed in the CEE countries, were quite similar. External reference pricing as well as internal reference pricing were common in mentioned countries. Positive reimbursement lists were valid in all countries of the CEE region, negative ones were rarely used; reimbursement decisions were regularly revised and updated in the majority of countries. Copayment was common and available levels of reimbursement differed within and between the countries and ranged from 20 to 100%. Risk-sharing schemes were often in use, especially in the case of innovative, expensive drugs. Generic substitution was also possible in all analyzed CEE countries, while some made it mandatory. HTA was carried out in almost all of the considered CEE countries and HTA dossier was obligatory for submitting a pricing and reimbursement application.Conclusions:Pricing and reimbursement requirements are quite similar in the CEE region although some differences were identified. HTA evaluations are commonly used in considered countries.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tesar, Tomas $u Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia.
- 700 1_
- $a Vostalova, Lenka $u Health Technology Assessment Department, Pricing and Reimbursement Regulation Branch, State Institute for Drug Control, Prague, Czechia.
- 700 1_
- $a Draganic, Pero $u Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia.
- 700 1_
- $a Manova, Manoela $u Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
- 700 1_
- $a Savova, Alexandra $u Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
- 700 1_
- $a Petrova, Guenka $u Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
- 700 1_
- $a Rugaja, Zinta $u The National Health Service, Ministry of Health, Riga, Latvia.
- 700 1_
- $a Männik, Agnes $u Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
- 700 1_
- $a Sowada, Christoph $u Health Sciences Faculty, Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Stawowczyk, Ewa $u Health Sciences Faculty, Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland.
- 700 1_
- $a Harsanyi, Andras $u National Institute of Health Insurance Fund Management, Budapest, Hungary. Department of Health Policy and Health Economics, Eötvös Loránd University, Budapest, Hungary.
- 700 1_
- $a Inotai, Andras $u Syreon Research Institute, Budapest, Hungary.
- 700 1_
- $a Turcu-Stiolica, Adina $u Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
- 700 1_
- $a Gulbinovič, Jolanta $u Departament of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Vilnius, Lithuania. State Medicine Control Agency, Vilnius, Lithuania.
- 700 1_
- $a Pilc, Andrzej $u Health Sciences Faculty, Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland. Departament of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 8, č. - (2017), s. 892
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29326583 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180404145508 $b ABA008
- 999 __
- $a ind $b bmc $g 1287575 $s 1006902
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 8 $c - $d 892 $e 20171218 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20180404